Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase EARLY_PHASE1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Breast Neoplasms 1Adenocarcinoma of the Pancreas 1

Interventions

Gemcitabine 169130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 32Fluorouracil 31pembrolizumab 30Capecitabine 30Leucovorin 27Irinotecan 27Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 18Bevacizumab 15Specimen Handling 12Magnetic Resonance Spectroscopy 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Paclitaxel 9Docetaxel 9Cetuximab 9Biopsy 9trametinib 8olaparib 8Sorafenib 8poly ICLC 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × paricalcitol × Clear all
NCT03520790 2025-03-21

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03883919 2022-10-05

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Washington University School of Medicine

Phase 1 Completed
20 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03300921 2022-03-31

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Terminated
3 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡